Status:

UNKNOWN

Effects of Immunonutrition on the Improvement of Postoperative Adjuvant Chemotherapy Related Adverse Reactions in Patients With Gastrointestinal Tumors

Lead Sponsor:

China Medical University, China

Conditions:

Gastrointestinal Tumors

Immunonutrition

Eligibility:

All Genders

18-75 years

Phase:

PHASE3

Brief Summary

Evaluate the effects of Suyusu (immunonutrition) in postoperative adjuvant chemotherapy for gastrointestinal cancer patients. The main endpoint of the study was the incidence of chemotherapy related a...

Eligibility Criteria

Inclusion

  • Subjects voluntarily and sign an informed consent form;
  • Age ≥ 18 years old and ≤ 75 years old;
  • Patients with stage II-III gastrointestinal malignancies with clear pathological diagnosis and undergoing radical surgery
  • No adjuvant chemotherapy received after surgery
  • The Eastern Cancer Collaborative Group's Physical State Score (ECOG) is 0-2 points;
  • No contraindications to chemotherapy and the use of fluorouracil based chemotherapy regimens;

Exclusion

  • Allergy to the components of immune nutrients, allergic constitution, or other inability to eat;
  • Participated in other drug or food clinical trials within 2 months prior to enrollment;
  • Having a history of immune deficiency, including HIV testing positive, or having other acquired or congenital immune deficiency diseases, or having a history of organ transplantation, or active infections that are not suitable for chemotherapy (as determined by the researcher);
  • Subjects cannot guarantee compliance after participating in the study;
  • Other researchers believe that it is not suitable for enrollment.

Key Trial Info

Start Date :

July 24 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2024

Estimated Enrollment :

324 Patients enrolled

Trial Details

Trial ID

NCT06085365

Start Date

July 24 2023

End Date

December 31 2024

Last Update

October 16 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The First Hospital of China Medical University

Shenyang, Liaoning, China, 110000